Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atibuclimab for Knee Osteoarthritis
NCT07481474Phase 1Not yet recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jan 2027
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised trial in knee osteoarthritis (OA) comparing Atibuclimab 20 mg/kg with Placebo (saline only) (2 arms). Primary endpoint: Rates of screening and randomization at 2 years. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
atibuclimab
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT07481474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07481474.